{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:34:32Z","timestamp":1790382872124,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13075-015-0814-z","type":"journal-article","created":{"date-parts":[[2015,10,22]],"date-time":"2015-10-22T17:40:21Z","timestamp":1445535621000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Methotrexate polyglutamates as a potential marker of adherence to long-term therapy in children with juvenile idiopathic arthritis and juvenile dermatomyositis: an observational, cross-sectional study"],"prefix":"10.1186","volume":"17","author":[{"given":"Ahmed F.","family":"Hawwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AbdelQader","family":"AlBawab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Rooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy R.","family":"Wedderburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Beresford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"McElnay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,22]]},"reference":[{"key":"814_CR1","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1521-6942(02)90234-2","volume":"16","author":"KJ Murray","year":"2002","unstructured":"Murray KJ, Lovell DJ. Advanced therapy for juvenile arthritis. Best Pract Res Clin Rheumatol. 2002;16:361\u201378.","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"814_CR2","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","volume":"59","author":"KG Saag","year":"2008","unstructured":"Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762\u201384.","journal-title":"Arthritis Rheum."},{"key":"814_CR3","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/art.20288","volume":"50","author":"N Ruperto","year":"2004","unstructured":"Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini F, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 2004;50:2191\u2013201.","journal-title":"Arthritis Rheum."},{"key":"814_CR4","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/art.20167","volume":"50","author":"CM Lambert","year":"2004","unstructured":"Lambert CM, Sandhu S, Lochhead A, Hurst NP, McRorie E, Dhillon V. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial. Arthritis Rheum. 2004;50:364\u201371.","journal-title":"Arthritis Rheum."},{"key":"814_CR5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/adc.88.3.197","volume":"88","author":"AV Ramanan","year":"2003","unstructured":"Ramanan AV, Whitworth P, Baildam EM. Use of methotrexate in juvenile idiopathic arthritis. Arch Dis Child. 2003;88:197\u2013200.","journal-title":"Arch Dis Child."},{"key":"814_CR6","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.2165\/00003495-200565100-00004","volume":"65","author":"CA Pilkington","year":"2005","unstructured":"Pilkington CA, Wedderburn LR. Paediatric idiopathic inflammatory muscle disease: recognition and management. Drugs. 2005;65:1355\u201365.","journal-title":"Drugs."},{"key":"814_CR7","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/art.1780371013","volume":"37","author":"ME Weinblatt","year":"1994","unstructured":"Weinblatt ME, Kaplan H, Germain BF, Block S, Solomon SD, Merriman RC, et al. Methotrexate in rheumatoid arthritis: a five-year prospective multicenter study. Arthritis Rheum. 1994;37:1492\u20138.","journal-title":"Arthritis Rheum."},{"key":"814_CR8","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/1529-0131(200109)44:9<1984::AID-ART346>3.0.CO;2-B","volume":"44","author":"S Cohen","year":"2001","unstructured":"Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis Rheum. 2001;44:1984\u201392.","journal-title":"Arthritis Rheum."},{"key":"814_CR9","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3899\/jrheum.090826","volume":"37","author":"ML Becker","year":"2010","unstructured":"Becker ML, Ros\u00e9 CD, Cron RQ, Sherry DD, Bilker WB, Lautenbach E. Effectiveness and toxicity of methotrexate in juvenile idiopathic arthritis: comparison of 2 initial dosing regimens. J Rheumatol. 2010;37:870\u20135.","journal-title":"J Rheumatol."},{"key":"814_CR10","first-page":"2501","volume":"31","author":"O Ortiz-Alvarez","year":"2004","unstructured":"Ortiz-Alvarez O, Morishita K, Avery G, Green J, Petty RE, Tucker LB, et al. Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis. J Rheumatol. 2004;31:2501\u20136.","journal-title":"J Rheumatol."},{"key":"814_CR11","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/ard.58.4.220","volume":"58","author":"M Dougados","year":"1999","unstructured":"Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schattenkirchner M, et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52\u00a0week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis. 1999;58:220\u20135.","journal-title":"Ann Rheum Dis."},{"key":"814_CR12","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/art.20278","volume":"50","author":"JM Kremer","year":"2004","unstructured":"Kremer JM. Toward a better understanding of methotrexate. Arthritis Rheum. 2004;50:1370\u201382.","journal-title":"Arthritis Rheum."},{"key":"814_CR13","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1172\/JCI112088","volume":"76","author":"BA Chabner","year":"1985","unstructured":"Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S, et al. Polyglutamation of methotrexate: is methotrexate a prodrug? J Clin Invest. 1985;76:907\u201312.","journal-title":"J Clin Invest."},{"key":"814_CR14","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/ard.60.8.729","volume":"60","author":"M Cutolo","year":"2001","unstructured":"Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis. 2001;60:729\u201335.","journal-title":"Ann Rheum Dis."},{"key":"814_CR15","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1172\/JCI116884","volume":"92","author":"BN Cronstein","year":"1993","unstructured":"Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest. 1993;92:2675\u201382.","journal-title":"J Clin Invest"},{"key":"814_CR16","doi-asserted-by":"crossref","first-page":"9720","DOI":"10.1016\/S0021-9258(17)39298-0","volume":"260","author":"CJ Allegra","year":"1985","unstructured":"Allegra CJ, Chabner BA, Drake JC, Lutz R, Rodbard D, Jolivet J. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem. 1985;260:9720\u20136.","journal-title":"J Biol Chem."},{"key":"814_CR17","first-page":"145","volume":"21","author":"H Schroder","year":"1988","unstructured":"Schroder H, Fogh K. Methotrexate and its polyglutamate derivatives in erythrocytes during and after weekly low-dose oral methotrexate therapy of children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 1988;21:145\u20139.","journal-title":"Cancer Chemother Pharmacol."},{"key":"814_CR18","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2165\/00003088-199630030-00002","volume":"30","author":"B Bannwarth","year":"1996","unstructured":"Bannwarth B, Pehourcq F, Schaeverbeke T, Dehais J. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet. 1996;30:194\u2013210.","journal-title":"Clin Pharmacokinet."},{"key":"814_CR19","first-page":"1573","volume":"20","author":"A Ravelli","year":"1993","unstructured":"Ravelli A, Di Fuccia G, Molinaro M, Ramenghi B, Zonta L, Regazzi MB, et al. Plasma levels after oral methotrexate in children with juvenile rheumatoid arthritis. J Rheumatol. 1993;20:1573\u20137.","journal-title":"J Rheumatol."},{"key":"814_CR20","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1373\/49.10.1632","volume":"49","author":"T Dervieux","year":"2003","unstructured":"Dervieux T, Orentas Lein D, Marcelletti J, Pischel K, Smith K, Walsh M, et al. HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis. Clin Chem. 2003;49:1632\u201341.","journal-title":"Clin Chem."},{"key":"814_CR21","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1002\/art.24034","volume":"58","author":"JM Dalrymple","year":"2008","unstructured":"Dalrymple JM, Stamp LK, O\u2019Donnell JL, Chapman PT, Zhang M, Barclay ML. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2008;58:3299\u2013308.","journal-title":"Arthritis Rheum."},{"key":"814_CR22","first-page":"313","volume":"17","author":"P Angelis-Stoforidis","year":"1999","unstructured":"Angelis-Stoforidis P, Vajda FJ, Christophidis N. Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin Exp Rheumatol. 1999;17:313\u201320.","journal-title":"Clin Exp Rheumatol."},{"key":"814_CR23","first-page":"S21","volume":"28","author":"B Cronstein","year":"2010","unstructured":"Cronstein B. How does methotrexate suppress inflammation? Clin Exp Rheumatol. 2010;28:S21\u20133.","journal-title":"Clin Exp Rheumatol"},{"key":"814_CR24","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1136\/ard.2004.033399","volume":"64","author":"T Dervieux","year":"2005","unstructured":"Dervieux T, Furst D, Lein DO, Capps R, Smith K, Caldwell J, et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis. 2005;64:1180\u20135.","journal-title":"Ann Rheum Dis."},{"key":"814_CR25","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1002\/art.20460","volume":"50","author":"T Dervieux","year":"2004","unstructured":"Dervieux T, Furst D, Lein DO, Capps R, Smith K, Walsh M, et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 2004;50:2766\u201374.","journal-title":"Arthritis Rheum."},{"key":"814_CR26","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00296-010-1774-x","volume":"32","author":"CF Pelajo","year":"2012","unstructured":"Pelajo CF, Sgarlat CM, Lopez-Benitez JM, Oliveira SK, Rodrigues MC, Sztajnbok FR, et al. Adherence to methotrexate in juvenile idiopathic arthritis. Rheumatol Int. 2012;32:497\u2013500.","journal-title":"Rheumatol Int."},{"key":"814_CR27","first-page":"S136","volume":"9","author":"CR Harley","year":"2003","unstructured":"Harley CR, Frytak JR, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care. 2003;9:S136\u201343.","journal-title":"Am J Manag Care"},{"key":"814_CR28","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1097\/MLR.0b013e318041384c","volume":"45","author":"CG Grijalva","year":"2007","unstructured":"Grijalva CG, Chung CP, Arbogast PG, Stein CM, Mitchel Jr EF, Griffin MR. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care. 2007;45:S66\u201376.","journal-title":"Med Care"},{"key":"814_CR29","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.semarthrit.2008.01.011","volume":"38","author":"LR Harrold","year":"2009","unstructured":"Harrold LR, Andrade SE. Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature. Semin Arthritis Rheum. 2009;38:396\u2013402.","journal-title":"Semin Arthritis Rheum."},{"key":"814_CR30","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/art.37917","volume":"65","author":"CA Waimann","year":"2013","unstructured":"Waimann CA, Marengo MF, de Achaval S, Cox VL, Garcia-Gonzalez A, Reveille JD, et al. Electronic monitoring of oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis: consequences of low adherence. Arthritis Rheum. 2013;65:1421\u20139.","journal-title":"Arthritis Rheum."},{"key":"814_CR31","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00296-009-1160-8","volume":"30","author":"A Thurah de","year":"2010","unstructured":"de Thurah A, Norgaard M, Harder I, Stengaard-Pedersen K. Compliance with methotrexate treatment in patients with rheumatoid arthritis: influence of patients\u2019 beliefs about the medicine: a prospective cohort study. Rheumatol Int. 2010;30:1441\u20138.","journal-title":"Rheumatol Int."},{"key":"814_CR32","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/art.22104","volume":"55","author":"KT April","year":"2006","unstructured":"April KT, Feldman DE, Platt RW, Duffy CM. Comparison between children with juvenile idiopathic arthritis and their parents concerning perceived treatment adherence. Arthritis Rheum. 2006;55:558\u201363.","journal-title":"Arthritis Rheum."},{"key":"814_CR33","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/1529-0131(199910)12:5<314::AID-ART2>3.0.CO;2-V","volume":"12","author":"PJ Degotardi","year":"1999","unstructured":"Degotardi PJ, Revenson TA, Ilowite NT. Family-level coping in juvenile rheumatoid arthritis: assessing the utility of a quantitative family interview. Arthritis Care Res. 1999;12:314\u201324.","journal-title":"Arthritis Care Res."},{"key":"814_CR34","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/art.22534","volume":"57","author":"DE Feldman","year":"2007","unstructured":"Feldman DE, de Civita M, Dobkin PL, Malleson P, Meshefedjian G, Duffy CM. Perceived adherence to prescribed treatment in juvenile idiopathic arthritis over a one-year period. Arthritis Rheum. 2007;57:226\u201333.","journal-title":"Arthritis Rheum."},{"key":"814_CR35","first-page":"434","volume":"135","author":"IF Litt","year":"1981","unstructured":"Litt IF, Cuskey WR. Compliance with salicylate therapy in adolescents with juvenile rheumatoid arthritis. Am J Dis Child. 1981;135:434\u20136.","journal-title":"Am J Dis Child."},{"key":"814_CR36","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/art.21603","volume":"53","author":"MA Rapoff","year":"2005","unstructured":"Rapoff MA, Belmont JM, Lindsley CB, Olson NY. Electronically monitored adherence to medications by newly diagnosed patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2005;53:905\u201310.","journal-title":"Arthritis Rheum."},{"key":"814_CR37","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1093\/rheumatology\/36.11.1218","volume":"36","author":"C Sturge","year":"1997","unstructured":"Sturge C, Garralda ME, Boissin M, Dore CJ, Woo P. School attendance and juvenile chronic arthritis. Br J Rheumatol. 1997;36:1218\u201323.","journal-title":"Br J Rheumatol."},{"key":"814_CR38","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/mpo.2950220307","volume":"22","author":"KA Skoglund","year":"1994","unstructured":"Skoglund KA, S\u00f6derhall S, Beck O, Peterson C, Wennberg M, Hayder S, et al. Plasma and urine levels of methotrexate and 7-hydroxymethotrexate in children with ALL during maintenance therapy with weekly oral methotrexate. Med Pediatr Oncol. 1994;22:187\u201393.","journal-title":"Med Pediatr Oncol."},{"key":"814_CR39","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0277-9536(92)90206-6","volume":"34","author":"JL Donovan","year":"1992","unstructured":"Donovan JL, Blake DR. Patient non-compliance: deviance or reasoned decision-making? Soc Sci Med. 1992;34:507\u201313.","journal-title":"Soc Sci Med."},{"key":"814_CR40","doi-asserted-by":"crossref","first-page":"e89908","DOI":"10.1371\/journal.pone.0089908","volume":"9","author":"AF Hawwa","year":"2014","unstructured":"Hawwa AF, Albawab A, Rooney M, Wedderburn LR, Beresford MW, McElnay JC. A novel dried blood spot-LCMS method for the quantification of methotrexate polyglutamates as a potential marker for methotrexate use in children. PLoS One. 2014;9:e89908.","journal-title":"PLoS One."},{"key":"814_CR41","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1136\/bmj.306.6887.1239","volume":"306","author":"HA Davies","year":"1993","unstructured":"Davies HA, Lennard L, Lilleyman JS. Variable mercaptopurine metabolism in children with leukaemia: a problem of non-compliance? BMJ. 1993;306:1239\u201340.","journal-title":"BMJ."},{"key":"814_CR42","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s00228-009-0700-1","volume":"65","author":"AF Hawwa","year":"2009","unstructured":"Hawwa AF, Millership JS, Collier PS, McCarthy A, Dempsey S, Cairns C, et al. The development of an objective methodology to measure medication adherence to oral thiopurines in paediatric patients with acute lymphoblastic leukaemia\u2014an exploratory study. Eur J Clin Pharmacol. 2009;65:1105\u201312.","journal-title":"Eur J Clin Pharmacol."},{"key":"814_CR43","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7","volume":"44","author":"AE Ede van","year":"2001","unstructured":"van Ede AE, Laan RF, Rood MJ, Huizinga TW, van de Laar MA, van Denderen CJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2001;44:1515\u201324.","journal-title":"Arthritis Rheum."},{"key":"814_CR44","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1002\/art.24653","volume":"60","author":"LK Stamp","year":"2009","unstructured":"Stamp LK, O\u2019Donnell JL, Chapman PT, Zhang M, Frampton C, James J, et al. Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment. Arthritis Rheum. 2009;60:2248\u201356.","journal-title":"Arthritis Rheum."},{"key":"814_CR45","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/art.27434","volume":"62","author":"ML Becker","year":"2010","unstructured":"Becker ML, van Haandel L, Gaedigk R, Lasky A, Hoeltzel M, Stobaugh J, et al. Analysis of intracellular methotrexate polyglutamates in patients with juvenile idiopathic arthritis: effect of route of administration on variability in intracellular methotrexate polyglutamate concentrations. Arthritis Rheum. 2010;62:1803\u201312.","journal-title":"Arthritis Rheum."},{"key":"814_CR46","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00280-009-1205-4","volume":"66","author":"T Adam de Beaumais","year":"2010","unstructured":"Adam de Beaumais T, Dervieux T, Fakhoury M, Medard Y, Azougagh S, Zhang D, et al. The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2010;66:653\u20138.","journal-title":"Cancer Chemother Pharmacol."},{"key":"814_CR47","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1093\/rheumatology\/keq216","volume":"49","author":"T Dervieux","year":"2010","unstructured":"Dervieux T, Zablocki R, Kremer J. Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis. Rheumatology (Oxford). 2010;49:2337\u201345.","journal-title":"Rheumatology (Oxford)"},{"key":"814_CR48","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/sj.jid.5700808","volume":"127","author":"E Campalani","year":"2007","unstructured":"Campalani E, Arenas M, Marinaki AM, Lewis CM, Barker JN, Smith CH. Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J Invest Dermatol. 2007;127:1860\u20137.","journal-title":"J Invest Dermatol."},{"key":"814_CR49","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/jid.2008.16","volume":"128","author":"RB Warren","year":"2008","unstructured":"Warren RB, Smith RL, Campalani E, Eyre S, Smith CH, Barker JN, et al. Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Invest Dermatol. 2008;128:1925\u20139.","journal-title":"J Invest Dermatol."},{"key":"814_CR50","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1365-2133.2008.08898.x","volume":"160","author":"RB Warren","year":"2009","unstructured":"Warren RB, Smith RL, Campalani E, Eyre S, Smith CH, Barker JN, et al. Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. Br J Dermatol. 2009;160:438\u201341.","journal-title":"Br J Dermatol."},{"key":"814_CR51","first-page":"CD000951","volume":"2","author":"Z Ortiz","year":"2000","unstructured":"Ortiz Z, Shea B, Suarez Almazor M, Moher D, Wells G, Tugwell P. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2000;2:CD000951.","journal-title":"Cochrane Database Syst Rev."},{"key":"814_CR52","first-page":"36","volume":"25","author":"Z Ortiz","year":"1998","unstructured":"Ortiz Z, Shea B, Suarez-Almazor ME, Moher D, Wells GA, Tugwell P. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis: a metaanalysis of randomized controlled trials. J Rheumatol. 1998;25:36\u201343.","journal-title":"J Rheumatol."},{"key":"814_CR53","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1016\/0006-2952(87)90651-4","volume":"36","author":"J Jolivet","year":"1987","unstructured":"Jolivet J, Faucher F, Pinard MF. Influence of intracellular folates on methotrexate metabolism and cytotoxicity. Biochem Pharmacol. 1987;36:3310\u20132.","journal-title":"Biochem Pharmacol."},{"key":"814_CR54","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1016\/0006-2952(85)90013-9","volume":"34","author":"DG Kennedy","year":"1985","unstructured":"Kennedy DG, Van den Berg HW, Clarke R, Murphy RF. The effect of leucovorin on the synthesis of methotrexate poly-\u03b3-glutamates in the MCF-7 human breast cancer cell line. Biochem Pharmacol. 1985;34:2897\u2013903.","journal-title":"Biochem Pharmacol."},{"key":"814_CR55","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/art.23144","volume":"58","author":"J Braun","year":"2008","unstructured":"Braun J, K\u00e4stner P, Flaxenberg P, W\u00e4hrisch J, Hanke P, Demary W, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008;58:73\u201381.","journal-title":"Arthritis Rheum."},{"key":"814_CR56","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/rheumatology\/36.1.86","volume":"36","author":"RA Hamilton","year":"1997","unstructured":"Hamilton RA, Kremer JM. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol. 1997;36:86\u201390.","journal-title":"Br J Rheumatol."},{"key":"814_CR57","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/ncpneph0810","volume":"4","author":"DJ Todd","year":"2008","unstructured":"Todd DJ, Weinblatt ME. Oral versus parenteral administration of methotrexate for the treatment of active RA. Nat Clin Pract Rheumatol. 2008;4:342\u20133.","journal-title":"Nat Clin Pract Rheumatol."},{"key":"814_CR58","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2165\/00128072-200204080-00003","volume":"4","author":"B Staples","year":"2002","unstructured":"Staples B, Bravender T. Drug compliance in adolescents: assessing and managing modifiable risk factors. Paediatr Drugs. 2002;4:503\u201313.","journal-title":"Paediatr Drugs."},{"key":"814_CR59","first-page":"1098","volume":"317","author":"RD Mosteller","year":"1987","unstructured":"Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317:1098.","journal-title":"N Engl J Med."}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0814-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T22:34:02Z","timestamp":1653345242000},"score":1,"resource":{"primary":{"URL":"http:\/\/arthritis-research.com\/content\/17\/1\/295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,22]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["814"],"URL":"https:\/\/doi.org\/10.1186\/s13075-015-0814-z","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,22]]},"article-number":"295"}}